Protein-Folding AI Platform Global Market Report 2026

The protein-folding artificial intelligence (AI) platform market size has grown exponentially in recent years. It will grow from $1.88 billion in 2025 to $2.48 billion in 2026 at a compound annual growth rate (CAGR) of 32%. The growth in the historic period can be attributed to increasing adoption of computational biology tools, growth in pharmaceutical research, availability of structural protein databases, rising demand for personalized medicine, development of high-performance computing systems.

The protein-folding artificial intelligence (AI) platform market size is expected to see exponential growth in the next few years. It will grow to $7.58 billion in 2030 at a compound annual growth rate (CAGR) of 32.2%. The growth in the forecast period can be attributed to integration of ai and deep learning for protein folding, expansion of cloud-based bioinformatics platforms, investment in specialized ai accelerators, growing academic and biotech research initiatives, demand for faster drug discovery cycles. Major trends in the forecast period include ai-driven protein structure prediction, high-performance computing integration, automated molecular modeling, cloud-based bioinformatics platforms, predictive drug discovery analytics.

The increasing adoption of personalized medicine is anticipated to drive the growth of the protein-folding artificial intelligence platform market in the coming years. Personalized medicine is a healthcare approach that tailors treatments based on an individual patient’s unique biological and personal characteristics. The rising use of personalized medicine is fueled by advancements in genomic technologies, which enable healthcare providers to rapidly and accurately analyze a patient’s genetic information, facilitating more targeted and effective therapies. A protein-folding artificial intelligence platform supports personalized medicine by predicting protein structures specific to each patient, guiding targeted drug selection and optimized treatment strategies. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, up from six approvals in 2022. The newly approved treatments for 2023 also comprised seven cancer drugs and three for other diseases and conditions. Thus, the growing adoption of personalized medicine is contributing to the expansion of the protein-folding artificial intelligence platform market.

The expanding research and development activities are expected to further propel the growth of the protein-folding artificial intelligence platform market in the future. Research and development (R&D) activities involve systematic efforts to develop, enhance, or innovate products, processes, or services through the application of scientific and technical knowledge. The rise in R&D activities is driven by increasing global competition, as organizations invest in innovation and advanced technologies to differentiate themselves and achieve sustainable long-term growth. These activities support protein-folding AI platforms by facilitating the creation and refinement of algorithms, improving protein structure predictions, and accelerating the discovery of new therapeutics. For instance, in April 2025, the Office for National Statistics, a UK-based government agency, reported that the UK government’s net spending on R&D rose to £17.4 billion ($22.1 billion) in 2023, up from £16.1 billion ($20.45 billion) in 2022, reflecting an 8.2% increase. Therefore, the increasing research and development activities are driving the growth of the protein-folding AI platform market.

In December 2025, Isomorphic Labs Ltd., a UK-based artificial intelligence and drug-discovery company utilizing protein-folding AI technology, formed a partnership with Eli Lilly and Novartis to advance AI-driven drug discovery and accelerate the development of new therapeutics. The collaboration seeks to employ AI-powered molecular design, improve drug target identification, and speed up the discovery of innovative medicines. Eli Lilly and Company is a US-based pharmaceutical company, and Novartis AG is a Switzerland-based pharmaceutical company, both focusing on the development of therapeutics across various disease areas.

Major companies operating in the protein-folding artificial intelligence (AI) platform market are Schrodinger Inc., XtalPi Inc., Isomorphic Labs Limited, Recursion Pharmaceuticals Inc., Nabla Bio Inc., Arzeda Corporation, Evozyne, ProteinQure Inc., Genesis Therapeutics Inc., Cradle Bio Inc., Profluent Inc., Evaxion Biotech A/S, Iambic Therapeutics Inc., Insilico Medicine Inc., Insitro Inc., Levitate Bio Inc., Shiru Inc., Tamarind Bio, Archon Biosciences, Neoncorte Bio, and Generate Biomedicines Inc.

North America was the largest region in the protein-folding artificial intelligence (AI) platform market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the protein-folding artificial intelligence (AI) platform market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the protein-folding artificial intelligence (AI) platform market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The protein-folding artificial intelligence (AI) platform market consists of revenues earned by entities by providing services such as structure prediction modeling, molecular interaction analysis, drug target identification support, protein stability, and mutation impact assessment. The market value includes the value of related goods sold by the service provider or included within the service offering. The protein-folding artificial intelligence (AI) platform market also includes sales of high-performance GPU servers, AI-optimized tensor processing units (TPUs), advanced data storage systems, and high-speed networking infrastructure. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

A protein-folding artificial intelligence (AI) platform is a computational system employing AI and machine learning to predict protein three-dimensional structures from amino acid sequences. These platforms process biological datasets, structural databases, and physicochemical properties to model protein folding, stability, and interactions with high speed and accuracy.

The key components of protein-folding artificial intelligence (AI) platforms include software, hardware, and services. Software leverages AI algorithms to predict protein folding patterns and three-dimensional structures, accelerating drug discovery and biological research. Solutions are deployed through on-premises and cloud models, applied in drug discovery, disease research, personalized medicine, biotechnology, academic research, and other applications, serving pharmaceutical and biotechnology companies, research institutes, healthcare providers, and other end users.

Tariffs have affected the protein-folding AI platform market by increasing the cost of importing high-performance computing hardware, specialized AI accelerators, and software tools. This impact is most pronounced in hardware and software segments, particularly in regions like North America, Europe, and Asia-Pacific that depend on imports for advanced AI infrastructure. Despite cost pressures, tariffs are driving local manufacturing and R&D investments, encouraging innovation in domestically developed AI platforms, and fostering a more resilient and diversified market.

The protein-folding artificial intelligence (AI) platform market research report is one of a series of new reports that provides protein-folding artificial intelligence (AI) platform market statistics, including protein-folding artificial intelligence (AI) platform industry global market size, regional shares, competitors with a protein-folding artificial intelligence (AI) platform market share, detailed protein-folding artificial intelligence (AI) platform market segments, market trends and opportunities, and any further data you may need to thrive in the protein-folding artificial intelligence (AI) platform industry. This protein-folding artificial intelligence (AI) platform market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.